convent
vaccin
strategi
highli
efficaci
sever
decad
reduc
mortal
morbid
due
infecti
diseas
bane
convent
vaccin
includ
whole
organ
larg
protein
appear
inclus
unnecessari
antigen
load
contribut
littl
protect
immun
respons
complic
situat
induc
allergen
andor
reactogen
respons
peptid
vaccin
attract
altern
strategi
reli
usag
short
peptid
fragment
engin
induct
highli
target
immun
respons
consequ
avoid
allergen
andor
reactogen
sequenc
convers
peptid
vaccin
use
isol
often
weakli
immunogen
requir
particul
carrier
deliveri
adjuv
articl
discuss
specif
advantag
consider
target
induct
immun
respons
peptid
vaccin
progress
develop
vaccin
variou
diseas
addit
also
discuss
develop
particul
carrier
strategi
inher
challeng
regard
safeti
combin
technolog
peptid
vaccin
vaccin
proven
mainstay
prevent
variou
deadli
infecti
diseas
histor
liveattenu
inactiv
form
microbi
pathogen
virus
bacteria
etc
use
induct
antigenspecif
respons
protect
host
subsequ
infect
base
pathogen
use
vaccin
formul
contain
anywher
ten
hundr
protein
howev
protect
immun
usual
depend
upon
select
protein
within
formul
wherea
major
protein
unnecessari
induct
protect
immun
furthermor
addit
protein
may
induc
allergen
andor
reactogen
respons
thu
emphas
need
elimin
vaccin
formul
rational
led
interest
subunit
vaccin
use
singl
select
protein
microb
vaccin
formul
induct
protect
immun
extens
logic
would
even
singl
protein
contain
mani
hundr
antigen
epitop
necessari
wherea
may
even
detriment
induct
protect
immun
creat
interest
peptid
contain
epitop
capabl
induc
posit
desir
cell
b
cell
mediat
immun
respons
use
vaccin
amino
acid
sequenc
synthes
form
immunogen
peptid
molecul
repres
specif
epitop
antigen
one
hand
sinc
epitop
antigen
determin
within
larger
protein
peptid
consid
suffici
activ
appropri
cellular
humor
respons
elimin
allergen
andor
reactogen
respons
addit
peptid
vaccin
use
induct
broadspectrum
immun
multipl
serolog
variant
serovar
strain
given
pathogen
formul
multipl
noncontigu
immunodomin
epitop
andor
epitop
conserv
differ
serovarsstrain
pathogen
hand
owe
rel
small
size
peptid
often
weakli
immunogen
therefor
requir
carrier
molecul
add
chemic
stabil
adjuv
induct
robust
immun
respons
allergen
andor
reactogen
carrier
molecul
increas
complex
peptid
vaccin
design
manufactur
peptid
vaccin
gener
consid
safe
cost
effect
compar
convent
vaccin
mani
peptid
vaccin
develop
vaccin
human
immunodefici
viru
hiv
hepat
c
viru
hcv
malaria
foot
mouth
diseas
swine
fever
influenza
anthrax
human
papilloma
viru
hpv
therapeut
anticanc
vaccin
pancreat
cancer
melanoma
nonsmal
cell
lung
cancer
advanc
hepatocellular
carcinoma
cutan
tcell
lymphoma
bcell
chronic
lymphocyt
leukemia
databas
publicli
privat
conduct
clinic
studi
maintain
clinicaltrialsgov
servic
us
nation
institut
health
around
clinic
studi
peptid
vaccin
prevent
therapeut
purpos
multipl
diseas
condit
regist
databas
midmarch
varieti
consider
need
made
design
peptid
vaccin
context
particular
vaccin
develop
first
foremost
among
identif
immunodomin
domain
epitop
capabl
induc
protect
immun
respons
term
humor
immun
andor
cell
mediat
immun
desir
antigen
immunodomin
epitop
chosen
context
b
cell
cytotox
helper
cell
exampl
one
suit
approach
prepar
protect
monoclon
antibodi
conserv
region
may
help
design
protect
well
therapeut
vaccin
cancer
vaccin
select
immunodomin
b
cell
epitop
import
hand
vaccin
intracellular
pathogen
virus
cancer
may
focu
identif
epitop
induc
cytotox
cell
respons
note
effici
induct
either
bcell
cytotox
cell
respons
induct
robust
helper
cell
respons
crucial
thu
epitop
select
direct
toward
induc
requir
effector
respons
b
cell
cytotox
cell
also
induct
helper
cell
respons
among
epitop
induc
specif
subset
immun
respons
next
challeng
would
identifi
right
epitop
peptid
activ
cell
magnitud
confer
protect
immun
addit
develop
broadspectrum
vaccin
multipl
serovar
pathogen
may
necessari
identifi
highli
conserv
immunodomin
epitop
anoth
issu
consid
process
present
associ
candid
peptid
vaccin
antigen
present
cell
cell
highli
mhcheterogen
human
popul
multipl
biochem
cellular
immuno
assay
design
util
select
candid
peptid
vaccin
variou
strategi
employ
either
silico
approach
experiment
approach
combin
follow
inher
complex
cost
use
experiment
approach
initi
stage
screen
led
research
seek
support
reliabl
costeffect
bioinformat
silico
tool
varieti
bioinformat
tool
use
predict
includ
limit
transloc
peptid
endoplasm
reticulum
mhci
cleavag
lysosom
compart
mhcii
bind
antigen
mhc
mhc
ii
hla
haplotyp
specif
recognit
cell
receptor
multipl
epitop
predict
algorithm
develop
briefli
describ
structur
resolut
desir
antigen
monoclon
antibodi
complex
use
nuclear
magnet
reson
xray
crystallographi
identifi
interact
atom
level
mass
spectrometri
identif
monoclon
antibodi
bind
antigen
epitop
use
silico
techniqu
map
whole
antigen
describ
structur
sequenc
epitop
comput
analysi
usual
done
first
exclud
antigen
nonbind
region
subsequ
map
amino
acid
residu
antigen
identifi
mass
spectrophotometri
analysi
crystal
structur
peptid
mimick
antigen
conform
structur
recogn
paratop
antibodi
usual
achiev
first
gener
specif
phage
display
librari
identifi
peptid
align
antigen
sequenc
subsequ
superimpos
structur
use
silico
tool
altern
approach
express
antigen
peptid
recombin
cdna
librari
screen
bind
specif
monoclon
antibodi
use
silico
tool
select
peptid
antigen
sequenc
align
antigen
sequenc
avail
structur
superimpos
algorithm
use
mimopro
mimox
pepitop
mimodb
predict
linear
b
cell
epitop
use
computer
algorithm
propens
scale
machinelearn
algorithm
combin
two
hybrid
algorithm
abcpr
ann
bepripr
hmm
advanc
algorithm
beddpro
svm
pssm
etc
usag
databas
contain
known
cell
epitop
peptid
includ
inform
respect
mhc
bind
affin
bind
antigen
involv
variou
clinic
condit
hla
restrict
host
specif
primari
sequenc
antigen
etc
case
develop
peptid
vaccin
select
correct
target
mhc
hla
critic
vaccin
candid
bind
major
hla
popul
imgt
hla
databas
give
inform
mhc
allel
polymorph
distribut
commun
use
purpos
varieti
structurebas
algorithm
also
avail
silico
predict
cell
epitop
roughli
classifi
homolog
model
protein
thread
proteinprotein
dock
predict
conform
epitop
done
use
sequenc
structur
base
bind
matric
silico
algorithm
discotop
cep
epc
pepito
seppa
epsvr
ellipro
blastmodel
epitpopia
cbtope
beepro
iedb
syfpeithi
bima
smm
ann
hmm
svm
propr
etc
identif
select
construct
candid
epitop
peptid
vaccin
antigen
follow
chemic
synthesi
antigen
peptid
synthes
peptid
subsequ
conjug
carrier
molecul
adjuv
requir
immunoprofil
result
construct
conduct
vitro
well
suitabl
anim
model
determin
safeti
efficaci
follow
progress
preclin
clinic
trial
success
vaccin
must
induc
strong
long
memori
humor
cellular
immun
respons
importantli
protect
diseas
target
therefor
import
evalu
whether
peptid
immunogen
induc
tcell
bcell
immun
earliest
peptid
vaccin
studi
came
virusderiv
tcell
epitop
report
late
identifi
mice
vaccin
small
synthet
peptid
recogn
cytotox
lymphocyt
ctl
result
also
show
peptid
present
mhci
molecul
vivo
consequ
abl
effect
induc
protect
tcell
respons
abl
resist
subsequ
relev
viru
challeng
later
studi
number
synthet
peptid
influenza
lcmv
sendai
viru
test
differ
group
mani
success
shown
induc
specif
cytotox
lymphocyt
immun
anim
peptid
recogn
cell
shown
select
extrem
sensit
one
amino
acid
chang
alter
specif
epitop
nonimmunogen
peptid
first
synthet
peptid
vaccin
provid
protect
came
studi
canin
parvoviru
dog
protect
efficaci
classic
vaccin
prepar
whole
viru
studi
also
shown
protect
mediat
peptid
vaccin
occur
distinct
tcell
mediat
fashion
without
requir
neutral
antibodi
sinc
specif
cellmedi
immun
also
play
central
role
control
tumor
growth
peptidebas
vaccin
also
design
use
tumor
therapeut
applic
sever
report
peptid
vaccin
success
control
tumor
growth
mous
model
studi
synthet
peptid
use
often
longer
amino
acid
minim
peptidesequ
recogn
cell
longer
peptid
need
trim
minim
mhci
bind
ligand
proteas
peptidas
profession
antigen
present
cell
apc
process
follow
load
onto
mhci
grove
fact
minim
peptid
use
studi
induc
lower
immun
respons
compar
longer
peptid
sinc
elicit
cell
respons
without
process
apc
exampl
bijker
et
al
demonstr
long
peptid
need
uptak
process
minim
epitop
abl
bind
mhci
molecul
induc
sustain
ctl
respons
vaccin
long
peptid
result
somewhat
delay
sustain
ctl
respons
kenter
et
al
also
prove
long
peptid
vaccin
hpv
superior
vaccin
short
peptid
aspect
confirm
later
studi
like
result
insuffici
effector
cell
respons
due
absenc
stimul
profession
apc
memori
helper
cell
elicit
impact
helper
cell
peptid
vaccin
proven
subsequ
studi
mani
model
system
depict
figur
exampl
lcmv
synthet
long
peptid
vaccin
studi
reveal
effect
lcmv
peptid
induc
lcmvspecif
cell
reactiv
depend
tcell
help
suggest
peptid
compris
helper
epitop
similar
result
came
peptid
vaccin
studi
peptid
vaccin
freund
incomplet
adjuv
fia
fail
induc
strong
peptidespecif
tcell
respons
mhcii
knockout
mice
peptid
compris
helper
epitop
overlap
ctl
epitop
data
suggest
activ
antigen
specif
helper
cell
peptid
compris
helperepitop
import
develop
peptid
vaccin
gener
protect
cell
respons
clearli
improv
addit
helper
peptid
longer
peptid
taken
profession
apc
proteolyt
process
load
onto
appropri
mhc
molecul
transport
cell
surfac
seem
logic
latest
design
peptid
vaccin
consist
multi
epitop
could
includ
mhc
ii
restrict
helper
epitop
recogn
cell
mhc
restrict
epitop
induc
helper
cell
ctl
includ
b
epitop
elicit
specif
cell
humor
respons
antibodi
respons
peptid
limit
linear
b
cell
epitop
would
challeng
gener
long
peptid
conform
resembl
nativ
protein
induct
protect
antibodi
howev
presenc
antibodi
abl
recogn
peptid
impli
antibodi
induc
peptid
vaccin
might
neutral
capac
enhanc
abil
mediat
ctl
function
antibodi
depend
cellmedi
cytotox
new
peptid
base
vaccin
must
consid
promot
peptid
secondari
structur
order
induc
specif
humor
respons
creativ
recent
design
includ
engin
distanc
repetit
epitop
peptid
abl
crosslink
b
cell
receptor
b
cell
prolifer
enhanc
peptid
antigen
structur
use
scaffold
flank
small
peptid
sequenc
possess
propens
fold
well
ad
li
linker
better
hla
present
peptid
epitop
taken
togeth
believ
possibl
peptid
vaccin
design
induc
cytotox
lymphocyt
also
elicit
effect
humor
cell
respons
peptidebas
vaccin
alon
even
compris
optim
bcell
tcell
epitop
poorli
immunogen
requir
adjuv
appropri
deliveri
system
effect
variou
particul
deliveri
system
studi
efficaci
deliveri
peptid
vaccin
candid
deliveri
system
also
serv
adjuv
modern
day
particul
deliveri
system
aim
overcom
shortcom
age
old
adjuv
alum
specif
limit
alum
lack
cellular
immun
system
stimul
degrad
freez
dri
possibl
advers
local
reaction
particul
vaccin
carrier
discuss
base
evolut
emuls
base
particul
carrier
vaccin
base
common
mechan
action
format
depot
inject
site
capabl
attract
immun
cell
emuls
singl
oilinwat
ow
waterinoil
wo
multipl
eg
waterinoilin
water
wow
stabil
emuls
deliveri
system
directli
proport
vaccin
safeti
efficaci
continu
presenc
antigen
depot
lymphoid
organ
releas
lowlevel
antigen
known
stimul
potent
immun
respons
highlevel
system
releas
antigen
lead
toler
util
deliv
peptid
vaccin
candid
critic
determin
process
manufactur
type
emuls
eg
multipl
emuls
wow
type
surfact
use
formul
emuls
emuls
base
adjuv
discuss
tabl
detail
literatur
review
reveal
emuls
popular
deliveri
method
variou
peptid
freund
complet
adjuv
cfa
fca
freund
incomplet
adjuv
ifa
fia
system
among
popular
one
increas
humor
cellular
immun
anim
human
cfa
compos
inactiv
dri
mycobacteria
wherea
ifa
devoid
mycobacteri
compon
process
emulsif
facilit
homogen
use
homogen
magnet
ultrasound
multipl
emuls
great
potenti
boost
immun
respons
depot
effect
inner
oil
compart
particul
adjuv
effect
provid
oil
droplet
variou
modif
exist
emuls
base
deliveri
system
promis
futur
eg
nh
contain
miner
oil
high
puriti
oleic
acid
deriv
sorbitan
monool
nh
wo
emuls
abl
protect
encapsul
peptid
antigen
peptidas
also
provid
slow
releas
peptid
give
sustain
antigen
stimul
similarli
novel
woo
multipl
emuls
system
contain
squalen
oil
encapsul
peptid
antigen
investig
efficaci
vaccin
deliveri
system
melanoma
immunotherapi
formul
easili
inject
display
fold
lower
viscos
prophylact
immun
activ
immun
increas
tumor
growth
delay
time
compar
wo
ifabas
peptid
vaccin
squalen
oil
hydrogen
dorm
squalan
oil
use
inner
compart
multipl
emuls
caus
inflammatori
respons
well
toler
site
inject
modif
emuls
system
increas
adjuv
includ
depovax
liposom
contain
adjuv
antigen
suspend
oil
glase
glucopyranosyl
lipid
adjuvantst
emuls
avail
liposom
phospholipid
bilay
structur
form
small
vesicl
mimick
cell
membran
aqueou
core
lipid
bilay
outsid
popular
extens
studi
deliveri
vehicl
peptid
antigen
specif
advantag
use
liposom
deliveri
vehicl
vaccin
candid
composit
tailor
biocompat
adapt
order
deliv
content
antigen
present
cell
apc
cross
present
facilit
promot
cellular
respons
liposom
coencapsul
immunostimul
adjuv
possibl
detail
review
liposom
deliveri
vehicl
peptid
antigen
avail
elsewher
composit
phospholipid
constitu
liposom
may
effect
quantiti
qualiti
immun
respons
produc
eg
amount
cholesterol
liposom
threshold
mol
cholesterol
found
play
role
induct
peptidespecif
immunolog
respons
surfac
decor
liposom
liposom
less
prefer
choic
deliveri
system
peptid
antigen
lower
entrap
effici
although
enhanc
immunogen
poorli
immunogen
protein
way
overcom
formul
issu
conjug
peptid
moieti
lipid
follow
incorpor
liposom
howev
incorpor
found
variabl
depend
upon
natur
lipid
anchor
lipopeptid
load
studi
wherein
antigen
peptid
conjug
liposom
surfac
success
studi
nagata
et
al
ovalbumin
ova
conjug
surfac
liposom
induc
ovaspecif
igg
antibodi
ige
antibodi
detriment
host
also
elicit
ctl
respons
presenc
cpg
ad
adjuv
inhibit
growth
tumor
mice
induct
ctl
respons
also
observ
liposom
surfac
decor
peptid
deriv
nonstructur
polyprotein
sever
acut
respiratori
syndrom
sar
associ
coronaviru
similar
studi
hepat
c
viru
deriv
peptid
coupl
surfac
liposom
found
confer
complet
protect
immun
mice
establish
long
term
memori
result
obtain
studi
also
replic
ova
antigen
found
produc
long
live
cell
without
cell
hand
case
peptid
liposom
formul
peptid
display
surfac
liposom
found
induc
humor
immun
respons
immunostimul
effect
liposom
mediat
protect
antigen
proteolyt
enzym
also
known
extend
halflif
antigen
blood
maximum
exposur
antigen
apc
occur
liposom
made
posit
charg
cation
liposom
coat
polyethylen
glycol
peg
promot
interact
apc
studi
cortesi
et
al
herp
simplex
viru
hsv
peptid
encapsul
cation
liposom
administ
ocularli
form
eye
drop
rabbit
infect
signific
protect
lethal
ocular
challeng
detect
along
absenc
reactiv
episod
latenc
surviv
anim
size
depend
movement
cation
liposom
inject
site
poplit
lymph
node
cell
prolifer
product
observ
studi
henriksenlacey
et
al
use
four
differ
size
cation
liposom
viz
cation
liposom
larger
size
found
promot
prolifer
low
product
wherea
liposom
size
around
nm
found
promot
product
liposom
also
made
ph
sensit
integr
fusogen
peptid
deliv
peptid
vaccin
cytosol
promot
ctl
respons
one
studi
involv
encapsul
ctl
epitop
peptid
hantaan
nucleocapsid
protein
human
papilloma
viru
ph
sensit
liposom
liposom
found
delay
growth
melanoma
cell
ctl
respons
found
maintain
approxim
week
similar
result
obtain
hiv
antigen
peptid
encapsul
ph
sensit
liposom
induct
ctl
highli
depend
effect
antigen
peptid
deliv
major
histocompat
complex
mhc
class
present
pathway
apc
hayashi
et
al
use
novel
approach
ad
er
insert
signal
sequenc
eriss
fusogen
liposom
promot
peptidemhc
class
associ
enhanc
peptid
transport
endoplasm
reticulum
er
fusogen
liposom
eriss
signal
found
prolong
epitop
present
enhanc
induct
vivo
tumor
immun
exampl
liposom
particul
carrier
clinic
develop
includ
consist
two
lipophl
compon
viz
qs
similar
group
colloid
liposom
explor
deliveri
antigen
virosom
transfersom
archeosom
niosom
cochleat
niosom
made
nonion
surfact
consid
stabl
convent
liposom
virosom
compos
assembl
viral
membran
protein
render
enhanc
bind
apc
promot
cytosol
deliveri
structur
virosom
compris
natur
occur
phospholipid
envelop
phospholipid
origin
influenza
viru
time
product
influenza
surfac
antigen
neuraminidas
hemagglutinin
integr
liposom
bilay
particl
size
nm
virosom
deliveri
antigen
apc
known
enhanc
mhc
class
mhc
class
ii
present
induc
band
tcell
respons
virosom
excel
adjuv
system
biodegrad
nontox
induc
antibodi
virosom
deliveri
system
quit
popular
increas
effect
malari
antigen
antigen
small
induc
immun
respons
inflex
v
virosom
adjuv
influenza
vaccin
subunit
base
virosom
technolog
develop
crucel
compani
leiden
netherland
formerli
berna
biotech
current
regist
countri
immun
influenza
age
group
also
market
name
infectovac
flu
germani
isiflu
v
itali
viroflu
unit
kingdom
immunostimulatori
complex
iscom
particul
antigen
deliveri
system
compos
antigen
cholesterol
phospholipid
saponin
around
nm
size
particul
adjuv
compris
cholesterol
phospholipid
saponin
without
antigen
iscom
compos
phospholipid
liposom
also
contain
saponin
adjuv
quil
iscom
load
hydrophob
antigen
strategi
encapsul
hydrophil
antigen
iscom
includ
coupl
antigen
iscom
use
amphipath
coupl
protein
conjug
hydrophil
fatti
acid
phospholipid
modif
protein
genet
engin
iscomss
known
induc
ctl
respons
nativ
well
modifi
immunogen
mediat
humor
well
cellmedi
immun
respons
recent
year
variou
polym
investig
deliveri
vaccin
natur
polym
avail
product
nanoparticl
includ
albumin
collagen
starch
chitosan
dextran
wherea
exampl
synthet
polym
includ
polymethylmethacryl
polyest
polyanhydrid
polyamid
synthet
polyest
polylactid
pla
polyglycolid
polyglocol
acid
pga
copolym
poli
lactidecoglycolid
plga
us
fda
approv
use
human
test
toxic
safeti
extens
anim
studi
popular
choic
biodegrad
polym
aliphat
polyest
poli
lactic
acid
pla
poli
glycol
acid
pga
poli
ecaprolacton
pcl
poli
hydroxybutyr
phb
copolym
particular
poli
lactidecoglycolid
plga
extens
investig
develop
nanoand
microparticl
encapsul
therapeut
drug
control
releas
applic
polyest
hydrolys
bodi
gener
biocompat
metaboliz
lactic
acid
glycol
acid
remov
bodi
citric
acid
cycl
owe
particul
natur
polymer
micro
nanoparticl
known
promot
uptak
transport
present
antigen
apc
also
found
elicit
cellular
humor
immun
biggest
advantag
offer
polym
base
antigen
deliveri
system
sustain
releas
period
week
month
encapsul
antigen
polym
matrix
rate
releas
antigen
encapsul
polymer
particl
control
rate
degrad
polym
matrix
turn
depend
composit
polym
matrix
molecular
weight
polym
size
particl
gener
hydrophob
interact
electrostat
forc
hydrogen
bond
van
der
waal
forc
combin
interact
avail
drive
forc
format
polym
complex
peptid
antigen
might
undergo
destabil
loss
immunogen
encapsul
process
strategi
target
polymer
particl
specif
arm
immun
system
dendrit
cell
dc
target
prolong
manner
use
encapsul
peptid
antigen
polymer
nanoparticl
increas
longev
antigen
increas
possibl
uptak
dc
exampl
strategi
includ
use
charg
polym
enhanc
encapsul
antigen
surfac
decor
particl
rgd
peptid
lectin
novel
approach
long
term
suppress
autoimmun
encephalomyel
eae
observ
peptid
antigen
peptid
administ
hybrid
nanoparticl
made
three
biodegrad
polym
viz
alginatechitosanplga
complex
given
onetim
inject
subcutan
mice
regul
product
cytokin
associ
product
natur
polym
chitosan
known
enhanc
bioavail
antigen
due
mucoadhes
properti
possibl
contribut
mechan
chitosan
shown
relax
intercellular
tight
junction
improv
paracellular
transport
antigen
chitosan
natur
occur
ideal
polym
nontox
natur
biocompat
biodegrad
produc
respons
specif
induc
cytokin
ad
viscou
solut
chitosan
found
gener
higher
antigenspecif
tcell
respons
chitosan
formul
also
abl
enhanc
adapt
immun
respons
peptid
vaccin
use
specif
antigen
like
gnrhi
poor
immunogen
greater
allogen
cell
prolifer
lymph
node
cell
mice
higher
antigenspecif
tcell
respons
interest
studi
chua
et
al
efficaci
chitosan
nanoparticl
micro
nano
size
encapsul
lhreleas
hormon
lhrh
investig
immunocontracept
vaccin
size
particl
found
enhanc
immunogen
rather
nonimmunogen
lhrh
without
addit
adjuv
ad
despit
merit
chitosan
one
disadvantag
poor
solubl
chitosan
water
howev
research
identifi
chitosan
deriv
chlorid
chitosan
hacc
complet
solubl
water
particul
system
use
deliv
vaccin
antigen
includ
carbon
nanotub
silicon
dioxid
nanoparticl
dendrim
ferritin
nanoparticl
peptid
nanocarri
gold
nanoparticl
liposomepolycationdna
lpd
complex
oligosaccharid
ester
deriv
o
microparticl
combin
system
eg
liposom
wo
emuls
investig
combin
advantag
emuls
microparticl
deliveri
system
order
formul
efficaci
deliveri
system
exampl
plga
microparticl
entrap
submicron
oilinwat
emuls
mf
vivo
studi
combin
system
indic
significantli
greater
antibodi
respons
individu
counterpart
also
lipidcalciumphosph
nanoparticl
exampl
multifunct
nanoparticl
abl
deliv
cargo
intracellularli
cytoplasm
lead
ctl
respons
interest
studi
jiang
et
al
plga
microparticl
coat
water
solubl
chitosan
conjug
cell
home
peptid
target
purpos
load
membran
protein
b
brachyspira
hyodysenteria
bmpb
model
vaccin
swine
dysenteri
oral
immun
microparticl
result
elev
secretori
iga
respons
mucos
tissu
system
igg
antibodi
respons
similar
studi
plga
microparticl
coat
chitosan
protamin
form
posit
charg
around
encapsul
ctlrestrict
peptid
siinfekl
deriv
albumin
upon
singl
immun
particl
mice
secret
increas
significantli
polyphosphazen
microparticl
truncat
secret
version
f
protein
encapsul
cpg
oligodeoxynucleotid
odn
innat
defens
regul
idr
peptid
microparticl
upon
intramuscular
intranas
immun
develop
significantli
higher
level
virusneutr
antibodi
sera
lung
higher
number
secret
cell
mice
immun
protein
alon
exampl
smart
microparticl
sensit
ph
releas
content
cytosol
formul
influenza
matrix
protein
found
prime
ctl
respons
first
approv
vaccin
adjuv
alum
develop
glenni
et
al
diphtheria
toxoid
absorb
alum
use
eight
decad
freund
develop
emuls
water
miner
oil
includ
kill
mycobacteria
known
freund
complet
adjuv
fca
gold
standard
adjuv
efficaci
howev
fca
induc
sever
local
necrot
ulcer
consid
toxic
human
use
without
ad
mycobacteria
oilbas
adjuv
known
freund
incomplet
adjuv
ifa
less
toxic
use
human
vaccin
formul
bacteri
compon
studi
adjuv
lipopolysaccharid
lp
lipophil
phospholipid
lipid
found
exhibit
adjuv
activ
number
natur
synthet
compound
demonstr
adjuv
activ
unfortun
mani
toxic
human
use
compar
alum
sever
new
approv
human
vaccin
fda
europ
virosom
monphosphoryl
lipid
mpl
alum
compos
squalen
produc
novarti
vaccin
diagnost
inc
present
adjuv
compon
influenza
vaccin
elderli
patient
fluad
virosom
consist
unilamellar
phospholipid
membran
reconstitut
empti
influenza
viru
envelop
licens
inflex
v
invivac
influenza
vaccin
hepat
vaccin
epax
trade
name
squalenebas
immunolog
adjuv
licens
pandem
flu
vaccin
pandemrix
glaxosmithklin
also
squalenebas
emuls
adjuv
present
adjuv
pandem
influenza
vaccin
also
develop
gsk
use
adjuv
viral
vaccin
includ
hepat
b
fendrix
hpv
cervarix
compris
tradit
alum
tolllik
receptor
tlr
agonist
mpl
adjuv
chemic
modifi
deriv
lipopolysaccharid
display
greatli
reduc
toxic
maintain
immunostimulatori
activ
lipopolysaccharid
potent
stimul
cell
antibodi
respons
wide
rang
clinic
trial
carri
mpl
result
dose
administ
individu
mpl
also
first
tlr
ligand
licens
human
vaccin
form
histori
safe
effect
use
licens
vaccin
technolog
consid
particul
peptid
vaccin
deliveri
safeti
particul
deliveri
strategi
highest
concern
select
particular
strategi
deliv
peptid
antigen
rout
administr
particul
deliveri
system
administ
play
vital
role
toxic
determin
common
rout
administr
vaccin
subcutan
intranas
intraven
transderm
transderm
rout
safest
meritori
term
needl
free
therefor
elimin
need
special
train
healthcar
worker
administ
vaccin
lower
cost
abil
confer
mucos
well
system
immun
increas
stabil
increas
shelf
life
polymer
particul
deliveri
system
hydrophob
polym
pegyl
polym
play
huge
role
determin
biodistribut
elimin
henc
toxic
hydrophob
polym
determin
membran
disrupt
properti
therefor
toxic
polym
polym
investig
shima
et
al
show
membran
disrupt
activ
endosom
ph
rang
requir
endosom
escap
entrap
antigen
cytosol
deliveri
antigen
induc
ctl
immun
respons
pegyl
polym
make
hydrophil
ie
reduc
hydrophob
wherea
decreas
distribut
liver
spleen
time
indic
nanoparticl
broken
clear
increas
safeti
poli
gammaglutam
acid
nanoparticul
system
studi
histopatholog
chang
subcutan
inject
acut
toxic
intraven
inject
found
safe
safeti
vaccin
deliv
via
particul
deliveri
system
usual
establish
give
repeat
administr
vaccin
therapeut
elev
dose
per
certain
guidelin
eg
oecd
criteria
use
evalu
safeti
may
includ
immedi
advers
event
ae
report
within
min
vaccin
solicit
unsolicit
ae
seriou
ae
clinic
laboratori
safeti
measur
vaccin
develop
complex
challeng
process
peptid
vaccin
provid
sever
advantag
comparison
convent
vaccin
peptid
vaccin
safe
econom
technolog
compar
tradit
vaccin
made
dead
attenu
pathogen
inactiv
toxin
recombin
subunit
peptid
vaccin
product
rel
inexpens
due
eas
product
simplist
composit
addit
peptid
vaccin
avoid
inclus
unnecessari
compon
possess
high
reactogen
host
lipopolysaccharid
lipid
toxin
moreov
peptid
vaccin
compos
variou
epitop
differ
antigen
integr
cell
b
cell
epitop
one
antigen
formul
despit
sever
advantag
peptid
typic
poorli
immunogen
use
alon
requir
next
gener
adjuv
overcom
problem
futur
peptid
vaccin
deliveri
strategi
may
target
combin
adjuv
formul
strategi
enhanc
abil
enhanc
antigen
uptak
novel
adjuv
stimul
innat
immun
induc
specif
adapt
immun
respons
howev
safeti
adjuv
remain
major
concern
one
could
devis
mean
overcom
safeti
issu
relat
use
adjuv
particul
peptid
vaccin
deliveri
system
peptid
vaccin
technolog
potenti
grow
next
gener
subunit
vaccin
work
support
midwestern
univers
faculti
startup
fund
nih
grant
american
heart
associ
midwest
affili
grant
akm
weidang
li
contribut
write
section
edit
section
format
manuscript
medha
joshi
contribut
write
section
smita
singhania
contribut
write
section
kyle
h
ramsey
contribut
section
edit
entir
manuscript
ashlesh
k
murthi
contribut
conceptu
review
articl
write
section
edit
entir
manuscript
author
declar
conflict
interest
